Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of Palazestrant on other drugs
8 evidence topics · 6 sources
In vitro CYP3A4 and transporter inhibition
“Low risk of transporter inhibition by compound 21 was determined by in vitro P-gp and BCRP assays (IC50 = 4 and >5 μM, respectively). No inhibitory activity was observed for the CYP 3A4 isoform (IC50 > 10 μM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ribociclib exposure with palazestrant 30 to 120 mg
Steady-state ribociclib parameters with and without palazestrant
| Steady-state parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
|---|---|---|
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |